Navigation Links
InterMune To Present At JMP Securities Healthcare Conference
Date:7/9/2012

BRISBANE, Calif., July 9, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Jonathan A. Leff, M.D.,  Executive Vice President, Research and Development of InterMune, will present at the JMP Securities 7th Annual Healthcare Conference in New York on Thursday, July 12 at 12:30 p.m. EDT. 

To access a live audio webcast of any of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
9. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... --  Synageva BioPharma Corp. (NASDAQ: GEVA ... disorders, announced today its presentation at the upcoming J.P. ... Francisco, CA. Sanj K. ... on Monday, January 12, 2015, at 9:00 a.m. PST ... and may be accessed from the "Webcasts & Presentations" ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... a DNA diagnostic test to identify women who, may benefit ... ... deCODEme(TM), REYKJAVIK, Iceland, April 27 Scientists from,deCODE genetics (Nasdaq: ... on chromosome 5 of the human genome that are,associated with risk of ...
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that ... stating that the Company is not in,compliance with the ... Nasdaq Global Market pursuant to Marketplace Rule 4450,(a)(5). This ... 22,2008, is a standard communication when the bid price ...
... EXTON, Pa., April 25 Isolagen(TM), Inc.,(Amex: ILE ) ... Global Healthcare Unplugged Conference on Thursday, May 1, 2008 at,3:40 ... May 2, 2008 at the,Ritz-Carlton Key Biscayne in Key Biscayne, ... audio can be accessed by,visiting http://www.isolagen.com . An ...
Cached Biology Technology:deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer 5Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... A study published in Cancer Prevention Research ... Cancer Research, identifies components of black raspberries with ... Comprehensive Cancer Center found that anthocyanins, a class ... stimulated apoptosis in the esophagus of rats treated ...
... Aromatase, the key enzyme required for the body to make ... biology work done by the Ghosh lab at the Hauptman-Woodward ... Debashis Ghosh,s solution of the three-dimensional structure of aromatase is ... the mechanism of synthesizing estrogen. In fact, the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3
... human omental preadipocytes are ... otherwise healthy donors. There ... diabetic cells. Please inquire ... media also available. Academic ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
...
Biology Products: